Immunovia AB, which develops blood tests for the early detection of cancer and autoimmune diseases, announced that it has received final approval to begin patient testing for the IMMray PanCan-d test, a blood test for detection of pancreatic cancer.
This approval was received from the Massachusetts Department of Public Health on August 3, 2021. Based in Lund, Sweden, Immunovia received its CLIA Certificate of Registration on June 21, 2021. As a result, Immunovia can immediately begin selling the IMMrayTM PanCan-d test for early detection of pancreatic cancer in the U.S. exclusively through its laboratory in Marlborough, MA.
By recognizing biomarker signatures, or signs of the disease in the blood, the IMMrayTM PanCan-d test has the potential to increase the survival of patients by detecting pancreatic cancer earlier, when surgical resection is possible, the company said.
